Articles and Videos
Loading...
September 21, 2021
Why BayMedica’s development of new cannabinoid analogs are suitable for pharmaceutical development
How will InMed’s acquisition of BayMedica strengthen InMed’s pharmaceutical programs? InMed CEO, Eric A. Adams, speaks with Shadd Dales of The Dales Report, to explain...
Source:
The Dales Report
September 21, 2021
Market differences between developing and commercializing a cannabinoid for pharmaceutical purposes or the health and wellness sector
Speaking with Shadd Dales of The Dales Report, Eric A. Adams, CEO of InMed, discusses the market differences between developing and commercializing a cannabinoid for...
Source:
The Dales Report
September 21, 2021
How the scalability of rare cannabinoids makes them more affordable
In this interview with The Dales Report, InMed CEO Eric A. Adams talks about how the scalability of synthesized rare cannabinoids will make them more...
Source:
The Dales Report
September 21, 2021
Is the cost of rare cannabinoids affordable enough to entice big consumer product companies?
InMed CEO, Eric A. Adams, is asked by Shadd Dales of The Dales Repot whether the cost of rare cannabinoids is scalable enough to entice...
Source:
The Dales Report
September 21, 2021
Is the industry ready for synthesized cannabinoids?
InMed CEO, Eric A. Adams, speaks with Shadd Dales of The Dales Report, and talks about whether the industry is ready for synthesized cannabinoids. Read...
Source:
The Dales Report
September 21, 2021
How will modern cannabinoid manufacturing techniques change cannabis industry?
What will the cannabis industry look like in 1-2 years? In this interview with Shadd Dales of @TheDalesReport, InMed CEO, Eric A. Adams, talks about...
Source:
The Dales Report